Glucagon non-aqueous injection - Xeris Pharmaceuticals

Drug Profile

Glucagon non-aqueous injection - Xeris Pharmaceuticals

Alternative Names: G-Pen; G-Pen Jr; G-Pen Mini; Injectable stable glucagon - Xeris; Xeris glucagon; XeriSol G-Pump

Latest Information Update: 21 Mar 2017

Price : $50

At a glance

  • Originator XERIS Pharmaceuticals
  • Developer Xeris Pharmaceuticals
  • Class Antihypoglycaemics; Pancreatic hormones
  • Mechanism of Action Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypoglycaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Hypoglycaemia

Most Recent Events

  • 15 Feb 2017 T1D Exchange Clinic Network Coordinating Center and Xeris Pharmaceuticals complete a phase II trial for Hypoglycaemia in USA (NCT02660242)
  • 10 Feb 2017 Phase-III clinical trials in Hypoglycaemia in USA (SC) (NCT02656069)
  • 01 Oct 2016 Phase-II clinical trials in Hypoglycaemia (Prevention, In infants) in USA (SC) (NCT02937558)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top